Rise Advisors’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$215K Buy
2,494
+1
+0% +$88 0.06% 100
2026
Q1
$227K Buy
2,493
+13
+0.5% +$1.19K 0.08% 89
2025
Q4
$223K Buy
2,480
+18
+0.7% +$1.71K 0.08% 90
2025
Q3
$243K Buy
2,462
+11
+0.4% +$1.09K 0.09% 87
2025
Q2
$224K Sell
2,451
-44
-2% -$4.25K 0.09% 89
2025
Q1
$282K Sell
2,495
-11
-0.4% -$1.18K 0.12% 73
2024
Q4
$265K Buy
2,506
+6
+0.2% +$644 0.13% 72
2024
Q3
$270K Buy
2,500
+5
+0.2% +$546 0.13% 71
2024
Q2
$271K Buy
2,495
+5
+0.2% +$589 0.14% 72
2024
Q1
$329K Buy
2,490
+128
+5% +$16K 0.18% 60
2023
Q4
$287K Buy
2,362
+5
+0.2% +$558 0.2% 49
2023
Q3
$265K Sell
2,357
-123
-5% -$15.6K 0.21% 43
2023
Q2
$361K Buy
2,480
+4
+0.2% +$544 0.28% 39
2023
Q1
$320K Buy
2,476
+5
+0.2% +$628 0.24% 45
2022
Q4
$315K Buy
2,471
+5
+0.2% +$580 0.25% 45
2022
Q3
$258K Buy
2,466
+6
+0.2% +$658 0.21% 54
2022
Q2
$258K Buy
2,460
+130
+6% +$15.4K 0.26% 51
2022
Q1
$298K Buy
2,330
+804
+53% +$96.9K 0.27% 51
2021
Q4
$188K Buy
+1,526
New +$200K 0.18% 68

Other funds holding ZBH

Rise Advisors's ZBH Position: Q2 2026 in Review

Rise Advisors increased its Zimmer Biomet (ZBH) stake by 0.04% in Q2 2026, buying an estimated $88 and bringing the position to 2,494 shares worth $215K. The position accounts for 0.06% of the portfolio, ranked #100.

Rise Advisors first reported a position in ZBH in Q4 2021 and has held it in 19 quarters since. The position peaked at $361K in Q2 2023. 906 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.

  • Rise Advisors held 2,494 shares of Zimmer Biomet worth $215K as of Q2 2026.
  • Rise Advisors bought 1 Zimmer Biomet share in Q2 2026, an estimated $88.
  • Zimmer Biomet made up 0.06% of Rise Advisors's portfolio in Q2 2026, its #100 holding.
  • Rise Advisors first reported a position in Zimmer Biomet in Q4 2021 and has held it in 19 quarters since.
  • Rise Advisors's Zimmer Biomet position peaked at $361K in Q2 2023.
  • 906 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.

Based on Rise Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.